Drug intelligence / Profile preview

DermaBind TL

Development stage: Phase 4
Lead developer: HealthTech Wound Care
Administration: Topical

Overview

DermaBind TL is a dehydrated, full-thickness placental membrane allograft developed by HealthTech Wound Care for the management of chronic, non-healing wounds. It is composed of the amnion, chorion, and the intermediate (spongy) layer, preserving a comprehensive extracellular matrix that includes over 400 proteins such as collagens, fibrins, and elastins. The allograft also contains essential growth factors and cytokines, including hyaluronic acid, transforming growth factor beta 1 (TGF-B1), hepatocyte growth factor (HGF), and interleukin-1 receptor antagonist (IL-1ra). It is intended for homologous use as a protective wound covering to facilitate healing in conditions such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The product is terminally sterilized and room-temperature stable, designed to provide a biological scaffold that supports cellular migration and tissue regeneration.

Brand names: DermaBind TL
Other names: HealthTech DermaBind TL

Targets

MET (Mesenchymal-epithelial transition factor receptor)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))TGFBR (TGF-beta receptor)

Beyond the preview

Go deeper on DermaBind TL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermaBind TL.

Explore the full profile